GYNECOLOGIC CANCERS
Latest News
Latest Videos
CME Content
More News
Genomic testing can help physicians in the treatment decision process for women with ovarian cancer. As more of these platforms become commercially available, however, physicians must also learn the similarities and differences between each of these tests.
Debra Richardson, MD, discussed the role of PARP inhibitor combinations for frontline maintenance of women with ovarian cancer at the 2019 SGO Winter Meeting.
Findings of a recent study suggest HPV testing should be incorporated into cervical cancer screening programs. The nested case-control Swedish study found that the presence of specific subtypes of HPV, namely HPV-16 and -18, were associated with a higher risk of developing high-grade cervical intraepithelial neoplasia in women under the age of 30.
According to recently announced topline findings, the confirmatory phase III SOLO-3 trial of olaparib has met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in objective response rate in patients with <em>BRCA</em>-mutant ovarian cancer who have relapsed on at least 2 prior lines of therapy
Danny Rischin, MD, MBBS, FRACP, discussed the results from a phase II trial looking at cemiplimab (Libtayo) in patients with advanced or recurrent cervical cancer.
At a planned interim analysis of the phase III JAVELIN Ovarian 100 study evaluating frontline avelumab in ovarian cancer, an independent panel determined the study would not meet its primary endpoint of progression-free survival. The co-developers of the PD-L1 inhibitor have announced they will terminate the trial on this basis.
Dasatinib (Sprycel) tablets has been approved by the FDA to be used in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.<br />
Several oncology experts discuss the FDA approvals they found most significant in 2018.
Maurie Markman, MD, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
David O’Malley, MD, discussed the findings from 2 clinical trials investigating PARP inhibition in ovarian cancer.
According to findings from a subgroup analysis of the phase III ARIEL3 study presented at the 2018 ESMO Congress, the PARP inhibitor rucaparib (Rubraca) improved progression-free survival as a maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer compared to placebo, despite the number prior of chemotherapy regimens.
Olaparib has been approved by the FDA as a maintenance therapy for patients with deleterious or suspected deleterious germline or somatic <em>BRCA</em>-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy, as approved by an FDA-approved companion diagnostic assay.
Danny Rischin, MD, discusses the potential of cemiplimab in patients with cervical cancer. The PD-1 inhibitor cemiplimab demonstrated antitumor activity and a tolerable safety profile as a monotherapy and in combination with hypofractionated radiotherapy for the treatment of patients with metastatic or recurrent cervical cancer.
Paul H. Sugarbaker, MD, FACS, FRCS, chief of the peritoneal surface malignancy program and director of the Center for Gastrointestinal Malignancies at Medstar Washington Hospital Center, discusses how surgical approaches have evolved in gynecologic cancers.
Based on findings from the phase III ARIEL3 trial, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending an expanded approval for single-agent rucaparib as a maintenance treatment for adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, David O’Malley, reviewed the treatment considerations and decisions he makes when treating patients with ovarian cancer. O’Malley explained to the group the factors that go into treatment decision making during the meeting based on a case scenario of a patient with high-grade serous carcinoma.
A look back at all the FDA news that happened in the month of November 2018, including several new approvals, priority reviews, a fast track designation, and an accelerated approval, across a variety of cancer types.
According to results from a small clinical study, checkpoint inhibitors in combination with chimeric antigen receptor T-cell therapy showed promise for improving CAR T-cell persistance in some patients with relapsed B-cell acute lymphoblastic leukemia. <br />
Patients with acute lymphoblastic leukemia saw a reduction in the risk for recurrence after receiving a stem cell transplant for the first time following treatment with CD19 chimeric antigen receptor T-cell therapy.
According to the findings from phase III JAVELIN Ovarian 200 trial, avelumab either alone or in combination with pegylated liposomal doxorubicin did not induce a statistically significant improvement in overall survival or progression-free survival in patients with platinum–resistant/refractory ovarian cancer compared to PLD monotherapy.
Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses how the ovarian cancer treatment paradigm has evolved over the past 30 years.
The side effect profile of olaparib tablets and the low rate of treatment discontinuation make it suitable for maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer, according to safety assessments from the SOLO-2 trial.
Based on data from the phase III SOLO-1 trial, a supplemental new drug application for olaparib tablets has been granted a priority review by the FDA for use as a maintenance therapy in patients with newly-diagnosed,<em> BRCA</em>-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.
Promising data with PARP inhibitors, specifically olaparib and niraparib, are showcasing this class of agents’ activity in early and later-line settings of ovarian cancer, explained Kathleen Moore, MD.
Susana M. Campos, MD, discusses her thoughts on the biggest advancements in ovarian cancer in 2018. PARP inhibitors are great at putting these patients in remission; however, the challenge with this lies in keeping them in remission.